Free tool
FAERS Monitor: Quviviq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214985 or its brand name (Quviviq, Daridorexant Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,777
Serious
996
36% of reports
Hospitalization
335
Death reported
78
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective482
- insomnia327
- nightmare281
- somnolence183
- fatigue171
- headache168
- product availability issue148
- abnormal dreams137
- feeling abnormal124
- inappropriate schedule of product administration122
- suicidal ideation100
- dizziness98
- nausea98
- wrong technique in product usage process91
- therapeutic product effect incomplete83
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 505 |
| 2023 | 1,154 |
| 2024 | 217 |
| 2025 | 402 |
| 2026 | 497 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nightmareSignal | 281 | 62.0 | 55.5 | 16,696 |
| product availability issueSignal | 148 | 49.5 | 42.3 | 6,954 |
| abnormal dreamsSignal | 137 | 37.8 | 32.1 | 4,848 |
| insomniaSignal | 327 | 9.3 | 8.4 | 2,445 |
| therapeutic product effect incompleteSignal | 83 | 8.8 | 7.2 | 571 |
| suicidal ideationSignal | 100 | 8.3 | 6.8 | 635 |
| somnolenceSignal | 183 | 6.9 | 6.0 | 923 |
| inappropriate schedule of product administrationSignal | 122 | 5.1 | 4.3 | 405 |
| feeling abnormalSignal | 124 | 3.9 | 3.3 | 270 |
| wrong technique in product usage processSignal | 91 | 3.4 | 2.8 | 153 |
| drug ineffectiveSignal | 482 | 2.8 | 2.6 | 580 |
| headacheSignal | 168 | 2.0 | 1.8 | 89 |
| fatigue | 171 | 1.7 | 1.4 | 46 |
| dizziness | 98 | 1.5 | 1.2 | 16 |
| nausea | 98 | 0.9 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.